A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection in Subjects With Alport Syndrome
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2018
At a glance
- Drugs RG 012 (Primary)
- Indications Hereditary nephritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Regulus Therapeutics
- 06 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 10 May 2018 According to a Regulus Therapeutics media release, data from this trial are expected by year-end 2018.
- 02 Apr 2018 Planned End Date changed from 1 Dec 2018 to 1 Sep 2019.